HCV Treatment: The
current treatment for hepatitis C, including outcomes, side effects and
treatment of various HCV populations
116. HCV-Genotype-Specific Influences
on Incident Diabetes: the Effect of Sustained Viral Response to Antiviral
117. Sustained Virologic Response is
Independently Associated with Improvement in Insulin Resistance in Genotype 1,
but not Genotype 2/3, Chronic HCV Patients.
124. A Novel Innate Immune Mechanism
of Action of Ribavirin in Antiviral Therapy.
Use of Telemedicine and the “Warm Line” for the Treatment of Hepatitis C
Infection (HCV) in the Correctional Setting to Reduce Barriers to Specialty
Nov 11, 2009)
774. Immediate versus delayed antiviral
treatment in patients with acute hepatitis C: A model-based decision analysis.
(updated Nov 2, 2009)
795. Clinical efficacy and cost
effectiveness analysis of peginterferon and ribavirin therapy in patients after
curative treatment for hepatocellular carcinoma associated with hepatitis C.
802. Long term follow-up of chronic
hepatitis C patients after interferon based anti-viral therapy. (updated Nov 11, 2009)
812. Retreatment With Peginterferon
(PEG-IFN) alfa-2b Plus Ribavirin (RBV) of Chronic Hepatitis C Genotype 1
Patients Who Were Nonresponders to Peginterferon alfa-2a: Final Results of
815. Retreatment of Chronic Hepatitis
C- Genotype 1-infected Relapsers to Peginterferon/ribavirin with Consensus
interferon/ribavirin or with Extended Duration Therapy Peginterferon/ribavirin.
819. Low-to-moderate alcohol
consumption has no impact on antiviral response to combination therapy in HCV
patients with genotype 2 or 3. (updated Nov 2, 2009)
820. Determinants of virologic
relapse following hepatitis C antiviral therapy: Analysis of the Canadian POWeR
831. Sustained Virological Responders
to Pegylated Interferon and Ribavirin Therapy may Show Transient HCV-RNA
Positivity when Adequately Followed Up. Clinical Associations and Significance
of this Phenomenon During 7-Year Follow-up of 506 Treated Patients.
873. Non-compliance with current
guidelines for treatment of chronic hepatitis C (CHC) is frequent in daily
practice and may lead to an increase in SVR: Results of a large prospective
901. Impact of therapeutic education
on the outcome of chronic hepatitis C treatment.
969. Preliminary Observational Study on
Efficacy and Tolerability Of PEG-IFN On 151 Pediatric and Adolescent Chronic
Hepatitis C Patients (updated Nov 13, 2009)
1554. Treatment of genotype 2 or 3
hepatitis C virus infection with pegylated interferon and weight based
ribavirin: A meta-analysis comparing short term [12-16 wks] vs. regular
duration [24 wks] treatment.
● HCV Populations
848. Analysis of Reasons for Treatment
Ineligibility in the IDEAL study: African Americans (AA) vs non-African
Americans (non-AA). (updated Nov 2, 2009)
889. Asian and White Patients With
Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon
(PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of
the REDD 2/3 Study.
829. Pegylated interferon alfa-2a
monotherapy for hemodialysis patients with acute hepatitis C.
849. Efficacy of a “on-treatment
viral response tailored regimen” with peginterferon (PegIFN) alfa 2b plus
ribavirin in naïve genotype 1 chronic hepatitis C (CHC) Mexican patients.
843. Extension of Combination Therapy
in HCV/HIV Co-infected Genotype 1 Patients: Effect on SVR.
805. Treatment of chronic hepatitis C
virus infection in IVDU: long term (4 year) follow up. (updated Nov 10, 2009)
813. Combination antiviral therapy
for chronic hepatitis C in illicit drug users: meta-analysis of prospective
887. Determinants of Engagement in
Care of Inner City HCV-Infected Injection Drug Users (IDUs). (updated Nov 10, 2009)
888. Treatment of recent hepatitis C
virus infection in a predominantly injection drug user cohort: the ATAHC Study.
891. Viral Hepatitis In IVDUs: A
14-Year Experience Of A Single Liver Unit - Epidemiological And Clinical Data.
894. The impact of chemical dependency
diagnosis and treatment on treatment of chronic hepatitis C (HCV) in patients
in a stable insured population.
61. Standard versus higher induction
doses of peginterferon alfa-2a (40KD) and/or higher ribavirin (RBV) in HCV G1
patients with high viral load and body weight ≥85 kg: Final results of
the PROGRESS study.
115. Outcome of Sustained Virological
Responders (SVR) and Non-responders in the Hepatitis C Antiviral Long-term
Treatment against Cirrhosis (HALT-C) Trial
1556. Highly Effective Peginterferon
Alpha-2a plus Ribavirin Combination Therapy for Chronic Hepatitis C in Patients
1561. Standard versus high dose
ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1)
HCV patients coinfected with HIV: Final results of the PARADIGM study.
850. Outcomes of a large, inclusive
population-based hepatitis C treatment program are similar to randomized
controlled trials: Interim results of the Canadian REDIPEN Program. (updated Nov 2,
880. Treatment compliance in patients
taking RibaPak® or ribavirin 200mg: Final analyses from the ADHERE registry.
(updated Nov 2,
● Side Effects
794. Global review of the rate of
interstitial pneumonitis among hepatitis virus C-infected patients treated with
pegylated interferon ± ribavirin. (updated Nov 2, 2009)
828. Thrombocytopenia during
treatment with peginterferon alfa and ribavirin for chronic hepatitis C is not
associated with severe bleedings.
● Treatment Outcomes
119. Long-term Survival of Sustained
Virologic Responders to Pegylated Interferon Therapy for Chronic Hepatitis C.